|1.||Molotkov, A O: 2 articles (05/2003 - 01/2003)|
|2.||Osipov, O V: 2 articles (05/2003 - 01/2003)|
|3.||Kirichuk, V F: 2 articles (05/2003 - 01/2003)|
|4.||Nodel', M L: 2 articles (05/2003 - 01/2003)|
|5.||Germanchuk, V G: 2 articles (05/2003 - 01/2003)|
|6.||Mal'tseva, G M: 2 articles (05/2003 - 01/2003)|
|7.||Zabrodskiĭ, P F: 1 article (05/2003)|
|8.||Rush, M L: 1 article (01/2003)|
|9.||Zabrodskii, P F: 1 article (01/2003)|
|10.||Shevchenko, V P: 1 article (11/2002)|
01/01/1989 - "application of 100 micrograms of T-activin at various intervals before and after infection resulted in a marked decrease in the number of cysticerci in peritoneal cavities of experimental mice (by 47.1-93.6%) compared to the controls. "
01/01/1991 - "[The correction of disorders in the cytoenzymatic status of the immunocytes in Shigella infection by using taktivin]."
04/01/1990 - "[The use of T-activin for the prevention of congenital influenzal infection in mice and the correction of the immune deficiency]."
01/01/1990 - "These data give grounds for including tactivin in combined therapy of patients with mixed gonorrheal-chlamydial urogenital infection."
01/01/1989 - "The effect of using T-activin in the therapy of the newborn with suppurative surgical infection."
01/01/1996 - "Tactivin accelerated the arrest of inflammatory process and improved the patients' status, particularly so in cases with the hypo- and hyperergic inflammations. "
01/01/1993 - "In control subjects (20 patients) on immunocorrection with tactivin inflammation persisted longer, urogenital complications were not cured, chlamydial recurrences occurred in 10% of the patients, immunological normalization was not reached."
01/01/1996 - "The effects of subcutaneous and endolymphatic tactivin (in doses of 1 ml of 0.01% solution daily for 7 days) on clinical and immunological parameters were studied in patients with acute inflammations in the maxillofacial area, running a normo-, hypo-, and hyperergic course. "
04/01/1994 - "[Experimental rationale for the use of T-activin for correction of immunodeficiency in the treatment of periapical inflammation]."
01/01/1991 - "T-activin successfully corrects the revealed immune disorders, stimulates metabolic processes in the cells and reduces inflammation and ameliorates the repair of the intestinal mucosa as well."
01/01/1989 - "[Efficacy of treating patients with disseminated forms of destructive pulmonary tuberculosis using chemical preparations and T-activin]."
09/01/1994 - "The paper presents results of the in vitro study of the immunomodulating effect of T-activin in 54 patients with active primary pulmonary tuberculosis, with the purpose of establishing criteria for initiating the therapy with this preparation. "
01/01/1995 - "Tactivin was tried in combined therapy of 49 new-onset cases with destructive pulmonary tuberculosis and gastrointestinal lesions. "
09/01/1994 - "[The immunological criteria in the expediency of prescribing T-activin to patients with primary pulmonary tuberculosis]."
01/01/1986 - "[T-activin in the complex treatment of patients with pulmonary tuberculosis]."
07/01/1991 - "The study was undertaken to examine myocardial morphological alterations in mice treated with T-activin in different periods of viral myocarditis. "
06/01/1988 - "[Effects of T-activin in viral myocarditis in animal experiments]."
01/01/1990 - "[The efficacy of taktivin in patients with viral myocarditis and dilated cardiomyopathy]."
06/01/1988 - "Optical, electron microscopic and immunological tests have shown that T-activin protects myocardium and modulates immune disorders in mice with viral myocarditis."
01/01/1990 - "The data obtained indicate that under the influence of the general therapy with T-activin cellular immunity manifested positive changes and the patients with viral myocarditis and DCMP felt better."
09/01/2001 - "Results are presented of studies on local nonspecific defence in patients with protracted pneumonia in the bronchoalveolar lavage fluid (BALF) during the course of conventional therapy involving the use of T-activin and extractum Glycerrhiza glabra L. "
01/01/1989 - "[Therapeutic and immunomodulating effects of T-activin in frequently ailing children with acute pneumonia]."
09/01/2001 - "has been found to be superior to T-activin in diminishing neutrophilic granulocytes count, increase in the BALF content of macrophages, lysozyme, s IgA; it proved to be endowed with an antiphospholipase activity, which facts predetermine apperant efficacy of the drug with respect to the lung local defence system in those patients presenting with protracted pneumonia."
|4.||Immunoglobulin A (IgA)
|5.||Deoxycytidine Monophosphate (DCMP)
|7.||Adrenal Cortex Hormones (Corticosteroids)
|8.||Circulating Thymic Factor
|10.||Immunologic Factors (Immunomodulators)
|3.||Drug Therapy (Chemotherapy)
|5.||Proximal Gastric Vagotomy